达托霉素辅助β-内酰胺治疗金黄色葡萄球菌菌血症的随机对照试验方案
DASH-RCT是一项随机双盲安慰剂对照试验,旨在评估在抗葡萄球菌β-内酰胺(头孢唑林或氯唑西林)标准治疗基础上加用5天达托霉素,能否缩短成人甲氧西林敏感金黄色葡萄球菌(MSSA)菌血症的菌血症持续时间。计划在麦吉尔大学健康中心招募约102例确诊MSSA菌血症的成人患者,主要假设是辅助达托霉素可减少菌血症持续时间。
要点
- 在β-内酰胺标准治疗基础上加用达托霉素,可能增强抗葡萄球菌活性。
- 试验针对成人MSSA菌血症,计划招募约102例,达托霉素疗程为5天。
- 主要假设是辅助达托霉素可缩短菌血症持续时间。
核心结论
- DASH-RCT将比较达托霉素辅助抗葡萄球菌β-内酰胺与安慰剂治疗MSSA菌血症的疗效和安全性。
研究设计与样本
- 随机、双盲、安慰剂对照试验,遵循SPIRIT和CONSORT指南设计。
- 在麦吉尔大学健康中心招募确诊MSSA菌血症的成人,计划约102例。
- 患者随机接受5天辅助达托霉素或安慰剂,同时接受标准治疗。
关键数值与推荐
- 入选标准:年龄18岁或以上,可接受头孢唑林或氯唑西林单药治疗,首次血培养采集后72小时内入组。
- 排除标准:对研究药物过敏、多种微生物菌血症、预计住院少于5天、医疗团队拒绝。
局限性
- 试验存在从感染出现到入组之间的延迟,以及诊断时可能未识别深部感染灶的问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staphylococcus aureus bacteremia is associated with significant morbidity and mortality. To treat this infection, the current standard of care includes intravenous anti-staphylococcal beta-lactam antibiotics and obtaining adequate source control. Combination therapy with an aminoglycoside or rifampin, despite early promise, can no longer be routinely recommended due to an absence of proven benefit and risk of harm. Daptomycin is a rapidly acting bactericidal antibiotic that is approved for the treatment of Staphylococcus aureus bacteremia as monotherapy but has not been shown to be superior to the current standard of care. As demonstrated in vitro, the addition of daptomycin to beta-lactam therapy may result in enhanced anti-staphylococcal activity. Our objective is to assess the efficacy and safety of prescribing the combination of daptomycin with cefazolin or cloxacillin for the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia in adults. We hypothesize that adjunctive therapy with daptomycin will reduce the duration of bacteremia in this population. METHODS: The DASH-RCT trial is a randomized, double blind, placebo-controlled trial designed per the Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) and Consolidated Standards of Reporting Trials (CONSORT) guidelines. We recruit adults with confirmed MSSA bacteremia, at the McGill University Health Center. Patients are eligible if they are 18 years or older, can receive cefazolin or cloxacillin monotherapy, and are enrolled within 72 h of the first blood culture being drawn. Exclusion criteria include anaphylaxis to study drugs, having polymicrobial bacteremia, anticipated hospital admission for < 5 days, and healthcare team refusal. While receiving standard of care, study patients are randomized to a 5-day course of adjunctive daptomycin or placebo. The trial began in December 2016 and is expected to end in December 2018, after recruiting an estimated 102 patients. DISCUSSION: The DASH-RCT will compare the use of daptomycin as an adjunct to an anti-staphylococcal beta-lactam versus placebo in the treatment of MSSA bacteremia. We believe that a short course of dual therapy will result in earlier eradication of bacteremia and that subsequent research could evaluate effects on metastatic infection, relapse, and/or mortality. Ongoing issues in the trial include a delay between presentation of infection, enrollment in the trial, and the potential for unrecognized deep foci of infection at diagnosis. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02972983 . Registered on 25 November 2016. Trial protocol: http://individual.utoronto.ca/leet/dash/dashprotocol.pdf.
引用
- Cheng MP, Lawandi A, Butler-Laporte G, et al. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29843781. doi:10.1186/s13063-018-2668-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。